01
Research objective definition
We define the biological question, therapeutic target and expected efficacy endpoints together with the client.
Demonstrating biological efficacy before clinical development requires experimental models that closely reproduce human neuronal function. Conventional in vitro systems often provide limited functional information, making it difficult to evaluate whether candidate compounds produce the desired biological response.
AxCellerate offers efficacy testing services based on advanced Brain-on-Chip technology and three-dimensional human-derived neuronal models. When an appropriate disease model is available, our platform enables researchers to investigate how compounds influence neuronal network activity, assess functional responses and generate biologically relevant efficacy data.
By combining human neuronal models, microtechnology and electrophysiological recordings, we help research teams obtain more predictive functional evidence to support compound selection and preclinical development decisions.
Highlights
Efficacy Testing supports research teams looking to evaluate the functional activity of candidate compounds in human-relevant neuronal models.
Each project is designed around the client's scientific objectives, disease model availability and required experimental endpoints.
Functional efficacy assessment in disease models
Evaluation of neuronal network responses
Comparison of candidate compounds
Dose-response investigations
Target validation studies
Translational neuroscience research
Generation of functional electrophysiological data
Our process
AxCellerate follows a structured process to evaluate candidate compounds in human-relevant neuronal models. From the definition of the therapeutic target and expected efficacy endpoints to model selection, Brain-on-Chip testing, functional readouts and final reporting, each step is designed to generate meaningful preclinical evidence for compound prioritisation and further development.
Discover how our Brain-on-Chip technology supports efficacy assessment in controlled, three-dimensional human-derived neuronal environments.
Each step is designed to help research teams investigate neurological mechanisms in a more human-relevant experimental environment.
We define the biological question, therapeutic target and expected efficacy endpoints together with the client.
The most appropriate human-derived neuronal model and disease context are selected to generate meaningful efficacy data.
Candidate compounds are evaluated using AxCellerate's Brain-on-Chip platform under controlled experimental conditions.
Electrophysiological recordings and functional neuronal responses are analysed to determine biological activity and treatment effects.
Experimental findings are organised into a comprehensive report supporting compound prioritisation and further preclinical development.
